Biotechnology: Biological Products (No Diagnostic Substances)

Business UpdateJul 16, 2026, 04:11 PM

DBV Technologies Files 2026 Half-Year Report with AMF

AI Summary

DBV Technologies announced the filing of its Half-Year Report for the semester ended June 30, 2026, with the French market authority, Autorité des Marchés Financiers (AMF). The report is available for consultation and download on the Company's website in the Investors/Financial Information section, as well as on the AMF website. This filing is a standard regulatory requirement for the late-stage biopharmaceutical company.

Key Highlights

DBV Technologies filed its Half-Year Report for the semester ended June 30, 2026.
The report was filed with the French market authority, Autorité des Marchés Financiers (AMF).
The 2026 Half-Year Report is accessible on the Company's website and the AMF website.

View SEC Filing

DBVT

Biotechnology: Biological Products (No Diagnostic Substances)

DBV Technologies S.A.

Price Impact